CatalystMarker
← board

NATR

distress 0/10 · well-funded / low risk
$20.42-2%today-27% from 52w high
naturessunshine.com806 employeesFounded 1972Lehi, UTPackaged Foods
Revenue
$123M
Liquidity
$88M
Runway
Shares 1y
+1%

Price & events

-16.8% over 6M
$19.68$23.74$27.80Jan 26Apr 26Jul 26471krating: DA Davidson: Buy (2026-05-11)rating: DA Davidson: Buy (2026-03-12)rating: Canaccord Genuity: Buy (2026-03-11)rating: Canaccord Genuity: Buy (2026-03-10)
CatalystRating changeDilutionFinancingdashed = today
-1.9%
1D
-4.3%
1W
-1.8%
1M
-24.0%
3M
-17.2%
6M
+34.3%
1Y
+25.5%
2Y
+15.6%
5Y
+49.0%
All

Overview

Market Cap
$359.08M
Volume
12.68K
52 Week Range
$13.14 – $27.80
Total Shares
17.58M
Float Shares
12.69M
Short %
4.88%
% Held by Insiders
3.07%
% Held by Institutions
88.22%
RVOL
0.11x
Beta
0.87

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 17,584,871 · 0 offerings/1y · 0 PIPEs
  • 2025-07-078-Kmaterial_agreement
  • 2025-06-278-Kmaterial_agreement
  • 2025-06-27424B5offering
  • 2025-06-25424B5offering
  • 2025-06-18EFFECTshelf_effective
  • 2025-06-09S-3shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2026-05-11DA DavidsonBuy
  • 2026-03-12DA DavidsonBuy
  • 2026-03-11Canaccord GenuityBuy
  • 2026-03-10Canaccord GenuityBuy
  • 2025-11-10DA DavidsonBuy
  • 2025-08-01Canaccord GenuityBuy

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.